PNPLA3 and metabolic dysfunction-associated steatotic liver disease: The fact that BemA has multiple mechanisms of action, including not only PPARα agonism, but also KHK inhibition and PNPLA3 induction, makes it an attractive candidate for NAFLD treatment.